FDA Widens Winrevair's Reach to Newly Diagnosed PAH Patients
- The FDA approved an updated label for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION trial data in adults recently diagnosed with pulmonary arterial hypertension.
- The trial found that adding Winrevair to background therapy substantially lowered the risk of clinical worsening events versus placebo.
- The update supports earlier use of Winrevair in the PAH treatment journey, marking the drug's third positive Phase 3 study.
💡 Points
Earlier-line positioning is what actually moves Winrevair's addressable market: shifting from a background-therapy add-on to newly diagnosed patients sets up a genuine first-line challenge to United Therapeutics' oral PAH franchise, and a third consecutive positive Phase 3 makes this look like a durable platform rather than a one-hit trial.
Merck nabs updated FDA label for soon-to-be-blockbuster Winrevair ↗